Efficacy and Safety of GLP-1RAs with or without Baseline SGLT2i: Post-hoc Analysis of the SUSTAIN 10 Trial

被引：0
|
作者：
Capehorn, Matthew
Catarig, Andrei-Mircea
Frenkel, Ofir
Hindsberger, Charlotte
Marre, Michel
Price, Hermione
Pratley, Richard E.
机构：
来源：
DIABETES | 2021年 / 70卷
关键词：
D O I：
10.2337/db21-647-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
647-P
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Efficacy and safety of mogamulizumab by patient baseline blood tumour burden: a post hoc analysis of the MAVORIC trial
    Cowan, R. A.
    Scarisbrick, J. J.
    Zinzani, P. L.
    Nicolay, J. P.
    Sokol, L.
    Pinter-Brown, L.
    Quaglino, P.
    Iversen, L.
    Dummer, R.
    Musiek, A.
    Foss, F.
    Ito, T.
    Rosen, J-P
    Medley, M. C.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2021, 35 (11) : 2225 - 2238
  • [22] Efficacy of liraglutide added to sodium-glucose cotransporter-2 inhibitors in type 2 diabetes, stratified by baseline characteristics: Post-hoc analysis of LIRA-ADD2SGLT2i
    Blonde, Lawrence
    Fainberg, Udi
    Kaltoft, Margit S.
    Mosenzon, Ofri
    Ramesh, Chethana
    Rea, Rosangela
    DIABETES OBESITY & METABOLISM, 2021, 23 (10): : 2234 - 2241
  • [23] Efficacy and Safety of Semaglutide for Type 2 Diabetes by Race and Ethnicity: A Post Hoc Analysis of the SUSTAIN Trials
    DeSouza, Cyrus
    Cariou, Bertrand
    Garg, Satish
    Lausvig, Nanna
    Navarria, Andrea
    Fonseca, Vivian
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2020, 105 (02): : 543 - 556
  • [24] Do GLP-1RAs and SGLT-2is reduce cardiovascular events in women with type 2 diabetes? A systematic review and meta-analysis
    Mishriky, B. M.
    Okunrintemi, V
    Jain, S.
    Sewell, K. A.
    Powell, J. R.
    Cummings, D. M.
    DIABETES & METABOLISM, 2021, 47 (01)
  • [25] Influence of the combination of SGLT2 inhibitors and GLP-1 receptor agonists on eGFR decline in type 2 diabetes: post-hoc analysis of RECAP study
    Muta, Yoshimi
    Kobayashi, Kazuo
    Toyoda, Masao
    Tone, Atsuhito
    Suzuki, Daisuke
    Tsuriya, Daisuke
    Machimura, Hideo
    Shimura, Hidetoshi
    Takeda, Hiroshi
    Yokomizo, Hisashi
    Takeshita, Kei
    Chin, Keiichi
    Kanasaki, Keizo
    Tamura, Kouichi
    Miyauchi, Masaaki
    Saburi, Masuo
    Morita, Miwa
    Yomota, Miwako
    Kimura, Moritsugu
    Hatori, Nobuo
    Nakajima, Shinichi
    Ito, Shun
    Tsukamoto, Shunichiro
    Murata, Takashi
    Matsushita, Takaya
    Furuki, Takayuki
    Hashimoto, Takuya
    Umezono, Tomoya
    Takashi, Yuichi
    Kawanami, Daiji
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [26] Comparative Safety and Effectiveness of GLP-1RA and SGLT2i Use in Adults with Type 2 Diabetes in US Clinical Practice
    Hoffman, Sarah R.
    Lanes, Stephan
    Quimbo, Tracey
    Papazian, Aanahit
    White, Jeff
    Fisher, Vicki
    Cziraky, Mark J.
    Crowley, Matthew J.
    Willey, Vincent
    DIABETES, 2024, 73
  • [27] Do GLP-1RAs and SGLT-2is reduce cardiovascular events in black patients with type 2 diabetes? A systematic review and meta-analysis
    Mishriky, Basem M.
    Powell, James R.
    Wittwer, Jennifer A.
    Chu, Jennifer X.
    Sewell, Kerry A.
    Wu, Qiang
    Cummings, Doyle M.
    DIABETES OBESITY & METABOLISM, 2019, 21 (10): : 2274 - 2283
  • [28] MONITORING THE COMPARATIVE SAFETY OF SGLT2I VS GLP-1 RA IN OLDER ADULTS WITH TYPE 2 DIABETES BY FRAILTY STATUS
    Kutz, Alexander
    Patorno, Elisabetta
    Gopalakrishnan, Chandrasekar
    Kim, Dae
    INNOVATION IN AGING, 2021, 5 : 208 - 208
  • [29] Efficacy and safety of traditional Chinese medicine and SGLT2i, GLP-1RA, and ACEI/ARB in the management of diabetic kidney disease: A systematic review and network meta-analysis
    Liu, Jiarong
    Xu, Jixiong
    RHEUMATOLOGY & AUTOIMMUNITY, 2025,
  • [30] GLP-1 RAs and SGLT2i: two antidiabetic agents associated with immune and inflammation modulatory properties through the common AMPK pathway
    Mazzieri, Alessio
    Basta, Giuseppe
    Calafiore, Riccardo
    Luca, Giovanni
    FRONTIERS IN IMMUNOLOGY, 2023, 14
12345